Thrombin generation and fibrin clot structure

Blood Reviews

Volumn 21, Issue 3, 2007, Pages 131-142

  Wolberg, Alisa S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Clot structure; Fibrin; Fibrinogen; Fibrinolysis; Hemophilia; Plasmin; Thrombin; Thrombosis

Indexed keywords

FIBRIN; THROMBIN;

ARTICLE; BLEEDING; BLOOD CLOT; CELL ACTIVITY; FIBRINOLYSIS; GELATION; HEMOSTASIS; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; WOUND HEALING;

BLOOD COAGULATION; FIBRIN; HEMORRHAGE; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN CONFORMATION; THROMBIN; THROMBOSIS;

EID: 34047229067     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.11.001     Document Type: Article

References (108)

1. Medved L.V., Gorkun O.V., and Privalov P.L. Structural organization of C-terminal parts of fibrinogen A alpha-chains. FEBS Lett. 160 (1983) 291-295
2. Ferry J.D., and Morrison P.R. Preparation and properties of serum and plasma proteins. VIII. The conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 69 (1947) 388-400
3. Betts L., Merenbloom B.K., and Lord S.T. The structure of fibrinogen fragment D with the 'A' knob peptide GPRVVE. J Thromb Haemost 4 (2006) 1139-1141
4. Rooney M.M., Mullin J.L., and Lord S.T. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen. Biochemistry 37 (1998) 13704-13709
5. Higgins D.L., and Shafer J.A. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J Biol Chem 256 (1981) 12013-12017
6. Blomback B., Hessel B., Hogg D., and Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275 (1978) 501-505
7. Shen L.L., Hermans J., McDonagh J., and McDonagh R.P. Role of fibrinopeptide B release: comparison of fibrins produced by thrombin and Ancrod. Am J Physiol 232 (1977) H629-H633
8. Torbet J. Fibrin assembly after fibrinopeptide A release in model systems and human plasma studied with magnetic birefringence. Biochem J 244 (1987) 633-637
9. Blomback B., Carlsson K., Fatah K., Hessel B., and Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75 (1994) 521-538
10. Carr M.E., and Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 11 (1978) 46-50
11. Hantgan R.R., and Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem 254 (1979) 11272-11281
12. Carr M.E., Shen L.L., and Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 16 (1977) 1-15
13. Wolberg A.S., Gabriel D.A., and Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrin 13 (2002) 533-539
14. Blomback B., Carlsson K., Hessel B., Liljeborg A., Procyk R., and Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 997 (1989) 96-110
15. Collet J.P., Park D., Lesty C., et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterio Thromb Vasc Biol 20 (2000) 1354-1361
16. Wolberg A.S., Monroe D.M., Roberts H.R., and Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 101 (2003) 3008-3013
17. Wolberg A.S., Allen G.A., Monroe D.M., Hedner U., Roberts H.R., and Hoffman M. High dose factor VIIa enhances clot stability in a model of hemophilia B. Brit J Haematol 131 (2005) 645-655
18. Hartmann A., Boukamp P., and Friedl P. Confocal reflection imaging of 3D fibrin polymers. Blood Cells Mol Dis 36 (2006) 191-193
19. Nair C.H., Shah G.A., and Dhall D.P. Effect of temperature, pH and ionic strength and composition on fibrin network structure and its development. Thromb Res 42 (1986) 809-816
20. Carr Jr. M.E., Gabriel D.A., and McDonagh J. Influence of Ca2+ on the structure of reptilase-derived and thrombin-derived fibrin gels. Biochem J 239 (1986) 513-516
21. Glover C.J., McIntire L.V., Brown III C.H., and Natelson E.A. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition. J Lab Clin Med. 86 (1975) 644-656
22. Carr M.E., and Gabriel D.A. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 96 (1980) 985-993
23. Marchi R., Lundberg U., Grimbergen J., et al. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser->Cys substitution associated with thrombosis. Thromb Haemost 84 (2000) 263-270
24. Collet J.-P., Soria J., Mirshahi M., et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 82 (1993) 2462-2469
25. Collet J.-P., Woodhead J.L., Soria J., et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophysical J 70 (1996) 500-510
26. Gabriel D.A., Muga K., and Boothroyd E.M. The effect of fibrin structure on fibrinolysis. J Biol Chem 267 (1992) 24259-24263
27. Carr Jr. M.E., and Alving B.M. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinol 6 (1995) 567-573
28. Tracy P.B., Peterson J.M., Nesheim M.E., McDuffie F.C., and Mann K.G. Interaction of coagulation factor V and factor Va with platelets. J Biol Chem 254 (1979) 10354-10361
29. Nesheim M.E., Pittman D.D., Wang J.H., Slonosky D., Giles A.R., and Kaufman R.J. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 263 (1988) 16467-16470
30. Ahmad S.S., Rawala-Sheikh R., and Walsh P.N. Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem 264 (1989) 3244-3251
31. Rawala-Sheikh R., Ahmad S.S., Ashby B., and Walsh P.N. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry 29 (1990) 2606-2611
32. Monroe D.M., Hoffman M., and Roberts H.R. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coag Fibrinol 7 (1996) 459-464
33. Hoffman M., Monroe D.M., Oliver J.A., and Roberts H.R. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86 (1995) 1794-1801
34. Liu W., Jawerth L.M., Sparks E.A., et al. Fibrin fibers have extraordinary extensibillity and elasticity. Science 313 (2006) 634
35. van 't Veer C., Golden N.J., Kalafatis M., Simioni P., Bertina R.M., and Mann K.G. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 90 (1997) 3067-3072
36. Al Dieri R., Peyvandi F., Santagostino E., et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 88 (2002) 576-582
37. Allen G.A., Wolberg A.S., Oliver J.A., Hoffman M., Roberts H.R., and Monroe D.M. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2 (2004) 402-413
38. Dargaud Y., Beguin S., Lienhart A., et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 93 (2005) 475-480
39. Wolberg AS. Thrombin Generation Assays: Understanding how the method influences the results. Thromb Res 2006;in press.
40. Shah G.A., Nair C.H., and Dhall D.P. Comparison of fibrin networks in plasma and fibrinogen solution. Thromb Res 45 (1987) 257-264
41. Carr M.E. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thrombosis and Haemostasis 59 (1988) 535-539
42. Torbet J. Fibrin assembly in human plasma and fibrinogen/albumin mixtures. Biochemistry 25 (1986) 5309-5314
43. Naski M.C., and Shafer J.A. A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem 266 (1991) 13003-13010
44. Elgue G., Sanchez J., Fatah K., Olsson P., and Blomback B. The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure. Thromb Res 75 (1994) 203-212
45. Wilf J., Gladner J.A., and Minton A.P. Acceleration of fibrin gel formation by unrelated proteins. Thromb Res 37 (1985) 681-688
46. Braaten J.V., Jerome W.G., and Hantgan R.R. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood 83 (1994) 982-993
47. Jerome W.G., Handt S., and Hantgan R.R. Endothelial cells organize fibrin clots into structures that are more resistant to lysis. Microsc Microanal 11 (2005) 268-277
48. Handt S., Jerome W.G., Tietze L., and Hantgan R.R. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood 87 (1996) 4204-4213
49. Reed G.L., Matsueda G.R., and Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thrombosis and Haemostasis 68 (1992) 315-320
50. Mosnier L.O., Buijtenhuijs P., Marx P.F., Meijers J.C., and Bouma B.N. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 101 (2003) 4844-4846
51. Pham T.D., Kaplan K.L., and Butler V.P. Immunoelectron microscopic localization of platelet factor 4 and fibrinogen in the granules of human platelets. J Histochem Cytochem 31 (1983) 905-910
52. Xi M., Beguin S., and Hemker H.C. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 62 (1989) 788-791
53. Xi M., Beguin S., and Hemker H.C. Importance of factor-IX-dependent prothrombinase formation-the Josso pathway-in clotting plasma. Haemostasis 19 (1989) 301-308
54. Sumner W.T., Monroe D.M., and Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81 (1996) 533-543
55. Butenas S., van't Veer C., and Mann K.G. "Normal" thrombin generation. Blood 94 (1999) 2169-2178
56. Kempton C.L., Hoffman M., Roberts H.R., and Monroe D.M. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 25 (2005) 861-866
57. Aird W.C. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 3 (2005) 1392-1406
58. Kumar R., Beguin S., and Hemker H.C. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 74 (1995) 962-968
59. Weitz J.I., Hudoba M., Massel D., Maraganore J., and Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86 (1990) 385-391
60. Weitz J.I., Leslie B., and Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97 (1998) 544-552
61. Torbet J. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro. Thromb Haemost 73 (1995) 785-792
62. von dem Borne P.A., Meijers J.C., and Bouma B.N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 (1995) 3035-3042
63. Panteleev M.A., Ovanesov M.V., Kireev D.A., et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 90 (2006) 1489-1500
64. Rodgers G.M., Greenberg C.S., and Shuman M.A. Characterization of the effects of cultured vascular cells on the activation of blood coagulation. Blood 61 (1983) 1155-1162
65. Rodgers G.M., Broze Jr. G.J., and Shuman M.A. The number of receptors for factor VII correlates with the ability of cultured cells to initiate coagulation. Blood 63 (1984) 434-438
66. Zwaginga J.J., de Boer H.C., MJ I.J., et al. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 10 (1990) 437-448
67. Ovanesov M.V., Ananyeva N.M., Panteleev M.A., Ataullakhanov F.I., and Saenko E.L. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost 3 (2005) 321-331
68. Carr Jr. M.E., Dent R.M., and Carr S.L. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 128 (1996) 83-88
69. Collet J.P., Mishal Z., Lesty C., et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?. Thromb Haemost 82 (1999) 1482-1489
70. Sugo T., Nakamikawa C., Yoshida N., et al. End-linked homodimers in fibrinogen Osaka VI with a B beta-chain extension lead to fragile clot structure. Blood 96 (2000) 3779-3785
71. Dunn E.J., Ariens R.A., and Grant P.J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48 (2005) 1198-1206
72. Dunn E.J., Philippou H., Ariens R.A., and Grant P.J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49 (2006) 1071-1080
73. Sixma J.J., and van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 58 (1984) 741-753
74. Cawthern K.M., van't Veer C., Lock J.B., Di Lorenzo M.E., Branda R.F., and Mann K.G. Blood coagulation in hemophilia A and hemophilia C. Blood 91 (1998) 4581-4592
75. Englert JM, Moen JL, Wolberg AS. Altered fibrinopeptide release produces thicker fibrin fibers and an abnormal fibrin clot structure in an in vitro model of hemophilia B. International Fibrinogen Workshop. 2004.
76. Bettigole R.E., Hampton J.W., and Bird R.M. Abnormal plasma clots in hemophilia. Thromb Diath Haemorrh 12 (1964) 331-337
77. He S., Blomback M., Jacobsson Ekman G., and Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 1 (2003) 1215-1219
78. Broze Jr. G.J., and Higuchi D.A. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88 (1996) 3815-3823
79. Mosnier L.O., Lisman T., van den Berg H.M., Nieuwenhuis H.K., Meijers J.C., and Bouma B.N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 86 (2001) 1035-1039
80. Lisman T., Mosnier L.O., Thierry Lambert T., et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 99 (2002) 175-179
81. Negrier C., and Hay C.R. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 26 (2000) 407-412
82. Monroe D.M., Hoffman M., Oliver J.A., and Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Brit J Haematol 99 (1997) 542-547
83. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
84. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Psaty B.M., Raghunathan T.E., and Vos H.L. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90 (1997) 1747-1750
85. Giordano P., De Lucia D., Coppola B., and Iolascon A. Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report. Acta Haematologica 102 (1999) 101-103
86. Kyrle P.A., Mannhalter C., Beguin S., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterio Thromb Vasc Biol 18 (1998) 1287-1291
87. Colucci M., Binetti B.M., Tripodi A., Chantarangkul V., and Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 103 (2004) 2157-2161
88. Fatah K., Hamsten A., Blomback B., and Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 68 (1992) 130-135
89. Fatah K., Silveira A., Tornvall P., Karpe F., Blomback M., and Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76 (1996) 535-540
90. Mills J., Mansfield M., and Grant P. Elevated fibrinogen in the healthy male relatives of patients with severe, premature coronary artery disease. Eur Heart J 23 (2002) 1276-1281
91. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 2567-2573
92. Greilich P.E., Carr M.E., Zekert S.L., and Dent R.M. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. American Journal of the Medical Sciences 307 (1994) 15-20
93. Mills J.D., Ariens R.A., Mansfield M.W., and Grant P.J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106 (2002) 1938-1942
94. Aoki I., Shimoyama K., Aoki N., et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol 27 (1996) 560-566
95. Nair C.H., Azhar A., Wilson J.D., and Dhall D.P. Studies on fibrin network structure in human plasma. Part II-Clinical application: diabetes and antidiabetic drugs. Thromb Res 64 (1991) 477-485
96. Jorneskog G., Egberg N., Fagrell B., et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39 (1996) 1519-1523
97. Meh D.A., Siebenlist K.R., and Mosesson M.W. Identification and characterization of the thrombin binding sites on fibrin. Journal of Biological Chemistry 271 (1996) 23121-23125
98. Mutch N.J., Robbie L.A., and Booth N.A. Human thrombi contain an abundance of active thrombin. Thromb Haemost 86 (2001) 1028-1034
99. Hogg P.J., and Jackson C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A 86 (1989) 3619-3623
100. Kumar R., Beguin S., and Hemker H.C. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thrombosis and Haemostasis 72 (1994) 713-721
101. de Bosch N.B., Mosesson M.W., Ruiz-Saez A., Echenagucia M., and Rodriquez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin 1). Thromb Haemost 88 (2002) 253-258
102. Owen J., Friedman K.D., Grossman B.A., Wilkins C., Berke A.D., and Powers E.R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72 (1988) 616-620
103. Badimon L., Chesebro J.H., and Badimon J.J. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 86 (1992) III74-III85
104. Banninger H., Lammle B., and Furlan M. Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. Biochem J 298 (1994) 157-163
105. Nehls V., and Herrmann R. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. Microvasc Res 51 (1996) 347-364
106. Shats E.A., Nair C.H., and Dhall D.P. Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis. Atherosclerosis 129 (1997) 9-15
107. Collen A., Koolwijk P., Kroon M., and van Hinsbergh V.W. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 2 (1998) 153-165
108. Weisel J.W., and Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 63 (1992) 111-128